Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade<sup>®</sup> or Inflectra<sup>®</sup> to Flixabi<sup>®</sup> in...

Full description

Bibliographic Details
Main Authors: Bas JM Peters, Anish Bhatoe, Adriane DM Vorselaars, Marcel Veltkamp
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cells
Subjects:
biosimilar
infliximab
sarcoidosis
TNF-α inhibitor
Online Access:https://www.mdpi.com/2073-4409/10/2/441

Internet

https://www.mdpi.com/2073-4409/10/2/441

Similar Items